SCHEMBL23296136

SCHEMBL23296136

O=c1ccn(Cc2ccc([N+](=O)[O-])cc2)c(=O)[nH]1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DBH P09172 1/20 0.54
DUT P33316 2/20 0.49
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
POLB P06746 1/20 0.47
ATM Q13315 1/20 0.47
LMNA P02545 4/20 0.46
CYP19A1 P11511 1/20 0.46
P2RX4 Q99571 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 4/20 0.43
MAPT P10636 3/20 0.43
IDO1 P14902 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KCNJ1 P48048 1/20 0.42
LOXL2 Q9Y4K0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29777943 0.79 L3MBTL1 (0.60) DBHDUTKMT2APOLBLMNA
SCHEMBL17371792 0.78 MAPT (0.51) DBHDUTKMT2APOLBALDH1A1
SCHEMBL20333609 0.78 PKM (0.51) DUT
SCHEMBL20334334 0.78 MAPT (0.58) DUTKMT2AMEN1POLBLMNA
SCHEMBL19370625 0.78 DUT (0.50) DUTLMNAALDH1A1
SCHEMBL5124651 0.78 DUT (0.50) DUTKMT2AMEN1LMNAALDH1A1
SCHEMBL2800300 0.77 DUT (0.59) DUTALDH1A1
SCHEMBL30072053 0.77 LMNA (0.56) DBHKMT2AMEN1LMNACYP19A1
SCHEMBL4486235 0.75 KMT2A (0.60) DBHKMT2AMEN1LMNAALDH1A1
SCHEMBL14825053 0.75 DBH (0.47) DBHKMT2AMEN1POLBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115785080-B Uracil parent nucleus compound and preparation method and application thereof 陕西盘龙药业集团股份有限公司 2024-10-11 CN disclosed
CN-115785080-A Uracil parent nucleus compound and preparation method and application thereof 陕西盘龙药业集团股份有限公司 2023-03-14 CN disclosed
CN-113968821-A Fluorouracil derivative and use thereof 聊城大学 2022-01-25 CN disclosed
US-11214564-B2 Compounds with thymine skeleton for use in medicine Technische Universität Dresden (DE) 2022-01-04 US disclosed
US-11214564-B2 Compounds with thymine skeleton for use in medicine Technische Universität Dresden (DE) 2022-01-04 US disclosed
EP-3819006-A1 COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE Technische Universität Dresden (DE) 2021-05-12 EP disclosed
US-20210130328-A1 NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE Technische Universität Dresden (DE) 2021-05-06 US disclosed
US-20210130328-A1 NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE Technische Universität Dresden (DE) 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130328-A1 NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE TMSB10, TMSB4X, TBCA DBH 4224/4885DUT 2722/4885KMT2A 4849/4885
US-11214564-B2 Compounds with thymine skeleton for use in medicine TMSB10, TMSB4X, TBCA DBH 4143/4885DUT 2372/4885KMT2A 4847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.